<DOC>
	<DOCNO>NCT01716026</DOCNO>
	<brief_summary>The purpose protocol determine wether initial protocol treatment subfoveal choroidal neovascularization associate High Myopia bevacizumab intravitreal injection effective use 3 dos vs use 1 single dose load period</brief_summary>
	<brief_title>Initial Treatment With Bevacizumab Choroidal Neovascularization Associated High Myopia</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Active subfoveal/juxtafoveal choroidal neovascularization high myopia confirm Fundus Fluorescein angiography Optical Coherence Tomography Best correct visual acuity loss le 6 month evolution , cause mainly neovascular lesion ( base investigator´s criterion ) No atrophy fibrotic component may prevent visual acuity improvement Patients previously treat Photodynamic Therapy allow participate study Signed inform consent Signed data protection consent Negative pregnancy test potential childbearing woman screen , accept contraceptive method whole study Previous vitreous surgery study eye Tractional maculopathy epiretinal membrane find Optical Coherence Tomography Media opacity may prevent correct fundus assessment Lack posterior capsule integrity pseudophakic patient Patients great possibility able attend study visit / follow visit procedure ( investigator´s criterion ) Patients previously treat intravitreal antiangiogenic injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>high myopia</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>